Navigation Links
TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights

f acute migraine.

-- Preclinical data were published in the October 17, 2007, issue of the

Journal of Neuroscience demonstrating that tezampanel may be effective

in reversing or preventing muscle spasticity and rigidity of spinal

ischemia. TorreyPines plans to initiate a Phase II clinical trial of

tezampanel for the treatment of muscle spasticity and rigidity

secondary to spinal cord trauma during the second half of 2008. This

will be the company's first clinical trial of tezampanel in a non-pain


-- TorreyPines initiated a Phase I maximum tolerated dose trial evaluating

NGX426, the oral prodrug of tezampanel. Dosing up to 150 mg has been

completed, and the study will continue to dose until either the maximum

tolerated dose is reached or up to a maximum of 210 mg. This clinical

trial is expected to be completed in the first half of 2008.

TorreyPines reported pharmacokinetic data from this clinical trial

showing that the area under the curve (AUC), which represents the total

amount of drug absorbed by the body, of a single, 80 mg, oral dose of

NGX426 is comparable to the AUC of a single, 40 mg, subcutaneous dose

of tezampanel.

-- A multiple dose Phase I clinical trial evaluating NGX267 was completed,

marking the third Phase I trial that demonstrated NGX267 is safe and

well tolerated. This multiple dose trial confirmed data from a

previous study in which statistically significant increases in salivary

flow were detected. TorreyPines initiated a Phase II clinical trial in

xerostomia, or dry mouth, secondary to Sjogren's syndrome in

March 2008.

Financial Results

Revenue for the three-month period ended December 31, 2007, was $2.5 million, compared to revenue of $2.5 million for the same period in 2006. Operating expenses for

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
2. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
3. TorreyPines Therapeutics Reports Third Quarter 2007 Results
4. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
6. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
7. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
8. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
9. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
10. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
11. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
Post Your Comments:
(Date:10/8/2015)... 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today announced its ... taking place in the month of October: ... RepliCel will be presenting at the annual Partnering ... Mesa to be held October 7-9 in ...
(Date:10/8/2015)... ... October 08, 2015 , ... Talon Innovations, a provider of ... other technology-driven industries, announces that it is one of three finalists for the Minnesota ... On Thursday, September 25 Talon Innovations was recognized as a nominee for this ...
(Date:10/7/2015)... PUNE, India , October 8, 2015 ... --> Medical biotechnology accounts for ... use of bioinformatics in drug discovery and ... with . ... --> On the basis of applications, ...
(Date:10/7/2015)... , ... October 07, 2015 , ... ... ) will present a public educational seminar on the latest advances in ... 10th from 1:00 pm – 3:00 pm at the Hilton Dallas/Southlake Town Square ...
Breaking Biology Technology:
... has closed its acquisition of California-based AccuImage Diagnostics Corp ... imaging software. , , Milwaukee Johnson Controls ... network and telephone services from Nortel Networks , a ... outsourcing nearly all the management of their network allows them ...
... banner year for venture capital investments in general, according to ... the National Venture Capital Association . Still, what does ... does it mean for the Midwest? Even more particularly, what ... ,Lets see if we can drill down to this level ...
... Su-Chun Zhang received another boost to his stem-cell ... Michael J. Fox Foundation . Zhang, an assistant professor of ... program, will receive approximately $340,000 from the foundations Cell Line ... course of his research. , , Fox The ...
Cached Biology Technology:
(Date:9/30/2015)... GARDENS, Fla. , Sept. 30, 2015  The ... this month issued another key ruling in favor of ... determination that Korean fingerprint scanner company Suprema and its ... Act of 1930, a trade provision that declares it ... import trade, by infringing two of Crossmatch,s patents, the ...
(Date:9/29/2015)... -- iDAvatars is excited to be named one of the first ... official announcement was recently made at an invite-only IBM ... San Francisco , where iDAvatars presented a demo of ... "It is both an honor and a privilege to ... market the cognitive power of IBM Watson in our product, ...
(Date:9/28/2015)... September 28, 2015 The global ... reach USD 12.03 billion by 2020, growing at a ... such as Backside Illumination (BSI) technique to improve picture ... forecast period.      (Logo: , ... chip to reduce loss and, thus, reduce the noise ...
Breaking Biology News(10 mins):
... The following highlights summarize research papers that have ... (GRL) and Journal of Geophysical Research-Atmospheres ... Coral reefs may start dissolving when atmospheric carbon ... Underground subatomic-particle measurements yield meteorological clues, Airborne acid ...
... life, but research at the Sahlgrenska Academy, University of Gothenburg, ... help from the egg to rejuvenate. The result is an ... of chromosomal abnormalities in the foetus is highly correlated to ... the age of the father. One possible explanation is that ...
... Researchers at the Tulane University School of Medicine, ... protease inhibitors (PIs), such as nelfinavir included in ... treatment of HIV-1 patients, induce deleterious effects on ... They report a significant decrease in the levels ...
Cached Biology News:
... Mutation Explorer processes up to 48 ... traces. Data input can be from either ... terminator or primer chemistries. The detection parameters ... analyst to analyst consistency. We have ...
... graphic manipulation of DNA sequences and sophisticated ... winning interface design that allows graphic manipulation ... sophisticated drawing capabilities for Mac and Windows ... Mapping Software" by the Biotechnology Software and ...
... Quality ISO 9001:2000 Certified USDA ... Precedures Validated, SOP's Training AALAS ... for All Procedures GLP Documentation Upon Request ... stop shopping point for all your custom ...
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Biology Products: